We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
-1.7%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$170M
AUM Growth
-$2.53M
Cap. Flow
+$4.95M
Cap. Flow %
2.9%
Top 10 Hldgs %
52.61%
Holding
53
New
12
Increased
19
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
STRM
Streamline Health Solutions
STRM
+$7.38M
2
ALKS icon
Alkermes
ALKS
+$5.2M
3
CVS icon
CVS Health
CVS
+$4.95M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.65M
5
COLL icon
Collegium Pharmaceutical
COLL
+$3.53M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$12.1M
2
UTHR icon
United Therapeutics
UTHR
+$7.07M
3
LH icon
Labcorp
LH
+$5.86M
4
AMGN icon
Amgen
AMGN
+$5.84M
5
MRK icon
Merck
MRK
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 96.32%
2 Consumer Staples 2.06%
3 Technology 1.03%
4 Miscellaneous 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LNTH icon
1
Lantheus
LNTH
$6.59B
$14.6M 8.59%
208,000
-42,000
-17% -$3.18M
MDRX
2
DELISTED
Veradigm Inc. Common Stock
MDRX
$10.4M 6.13%
685,000
+135,000
+25% +$2.18M
PCRX icon
3
Pacira BioSciences
PCRX
$1.05B
$10.4M 6.09%
195,000
+20,000
+11% +$1.11M
PRGO icon
4
Perrigo
PRGO
$2.07B
$9.09M 5.34%
255,000
+55,000
+28% +$2.21M
THC icon
5
Tenet Healthcare
THC
$21.3B
$9.03M 5.3%
175,000
+15,000
+9% +$890K
CERS icon
6
Cerus
CERS
$522M
$8.73M 5.13%
2,425,000
+425,000
+21% +$2.03M
SIBN icon
7
SI-BONE Inc
SIBN
$829M
$8.03M 4.72%
460,000
-75,000
-14% -$1.2M
ANGO icon
8
AngioDynamics
ANGO
$628M
$6.65M 3.9%
325,000
+5,000
+2% +$110K
PHR icon
9
Phreesia
PHR
$679M
$6.63M 3.89%
260,000
+15,000
+6% +$374K
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$12.9B
$6.02M 3.53%
71,000
+41,000
+137% +$3.65M
SNY icon
11
Sanofi
SNY
$106B
$5.89M 3.46%
155,000
+60,000
+63% +$2.67M
STRM
12
DELISTED
Streamline Health Solutions
STRM
$5.87M 3.45%
+328,725
New +$7.38M
CI icon
13
Cigna
CI
$74.7B
$5.55M 3.26%
20,000
-43,000
-68% -$12.1M
VTRS icon
14
Viatris
VTRS
$19.4B
$5.54M 3.25%
650,000
+300,000
+86% +$2.95M
BVS icon
15
Bioventus
BVS
$961M
$5.25M 3.08%
750,001
– –
COLL icon
16
Collegium Pharmaceutical
COLL
$766M
$4.81M 2.82%
300,000
+200,000
+200% +$3.53M
CVS icon
17
CVS Health
CVS
$124B
$4.77M 2.8%
+50,000
New +$4.95M
ALKS icon
18
Alkermes
ALKS
$7.73B
$4.47M 2.62%
+200,000
New +$5.2M
JAZZ icon
19
Jazz Pharmaceuticals
JAZZ
$16B
$4M 2.35%
30,000
+5,000
+20% +$760K
DCGO icon
20
DocGo
DCGO
$39.8M
$3.72M 2.18%
375,000
+200,000
+114% +$1.81M
TPB icon
21
Turning Point Brands
TPB
$1.51B
$3.5M 2.06%
165,000
-25,000
-13% -$620K
ATRC icon
22
AtriCure
ATRC
$2.62B
$2.64M 1.55%
67,500
-32,500
-33% -$1.49M
RIGL icon
23
Rigel Pharmaceuticals
RIGL
$909M
$2.36M 1.39%
200,000
– –
ICUI icon
24
ICU Medical
ICUI
$4.19B
$2.26M 1.33%
15,000
+2,000
+15% +$333K
MRK icon
25
Merck
MRK
$371B
$2.15M 1.26%
25,000
-50,000
-67% -$4.46M
1
2 3

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q3 2022 Portfolio in Review

As of Q3 2022, Tamarack Advisers held 53 positions worth $170M, down 1.5% from $173M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Tamarack Advisers's Q3 2022 filing shows 12 new, 19 increased, 9 reduced and 7 closed positions. Its largest new stake was Streamline Health Solutions: 328,725 shares worth $5.87M. The largest sale was Cigna, an estimated $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Consumer Staples and Technology.

  • Tamarack Advisers's largest Q3 2022 buy was Streamline Health Solutions: 328,725 shares worth $5.87M.
  • Tamarack Advisers added most to BioMarin Pharmaceuticals in Q3 2022, an estimated $3.65M increase.
  • Tamarack Advisers's biggest Q3 2022 reduction was Cigna, cutting an estimated $12.1M.
  • Tamarack Advisers fully exited United Therapeutics in Q3 2022, selling an estimated $7.07M.
  • Tamarack Advisers's ten largest holdings make up 53% of its $170M portfolio in Q3 2022.
  • Tamarack Advisers opened 12 new positions and closed 7 in Q3 2022.
  • Tamarack Advisers's portfolio value fell 1.5% quarter-over-quarter to $170M.

Based on Tamarack Advisers's 13F filing for Q3 2022, filed 15 Nov 2022.